title: Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element.
abstract: OBJECTIVE
  To investigate the effect of peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands on transcription and secretion of regulated upon activation normal T-cell expressed and secreted (RANTES) in endometriotic stromal cells.
  
  
  METHODS
  Controlled laboratory study.
  
  
  METHODS
  Academic research laboratory. Women in the follicular phase of the menstrual cycle undergoing laparoscopic resection for endometriosis. [1]. Transient transfection of endometriotic stromal cells with RANTES promoter vectors with and without a mutagenized PPAR-gamma response element (PPRE), then treatment with PPAR-gamma ligands; [2]. co-incubation of cells with PPAR-gamma ligands.
  
  
  METHODS
  RANTES promoter activity and RANTES secretion. In endometriotic stromal cells, addition of PPAR-gamma ligands (rosiglitazone and 15 deoxy-Delta(12,14) prostaglandin J(2)) inhibited RANTES promoter activity by 51% and 50%, respectively. In cells transfected with the same promoter after site-directed mutagenesis of the 5' PPRE, addition of PPAR-gamma ligands failed to inhibit promoter activity. When endometriotic stromal cells were treated with PPAR-gamma ligands, a decrease in RANTES secretion by 51% and 20%, respectively, was observed. CONCLUION(S): The PPAR-gamma ligands inhibit RANTES transcription and protein production in endometriotic stromal cells. Transcriptional repression appears to be mediated through a specific PPRE at -344 to -322 bp upstream from the RNA polymerase start site.
authors.affiliation: Center for Reproductive Sciences., University of California, San Francisco, San Francisco, California, USA. eapritts@wisc.edu
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Pritts
authors.forename: Dong
authors.initials: D
authors.lastname: Zhao
authors.forename: Sae H
authors.initials: SH
authors.lastname: Sohn
authors.forename: Victor A
authors.initials: VA
authors.lastname: Chao
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Waite
authors.forename: Robert N
authors.initials: RN
authors.lastname: Taylor
mesh_terms: D001483:Base Sequence / Q000235:genetics; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors* / Q000235:genetics*; D004715:Endometriosis / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008024:Ligands; D016297:Mutagenesis, Site-Directed; D011401:Promoter Regions, Genetic / Q000502:physiology*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000494:pharmacology; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D020218:Response Elements / Q000235:genetics; D000077154:Rosiglitazone; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism*; D013844:Thiazoles / Q000494:pharmacology; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000378:metabolism*; D014162:Transfection
chemical_list: C097240:15-deoxy-delta(12,14)-prostaglandin J2; D018946:Chemokine CCL5; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077154:Rosiglitazone; D015230:Prostaglandin D2